Latest Oncology News

Page 3 of 23
Prescient Therapeutics reported a 62.8% increase in half-year losses to nearly $4 million, driven by intensified clinical development of its PTX-100 cancer therapy. The company bolstered its balance sheet with a $9.85 million capital raise while securing key regulatory milestones in Europe and the US.
Ada Torres
Ada Torres
24 Feb 2026
TrivarX Limited reported a $1.26 million half-year loss as it completed the acquisition of Stabl-Im brain imaging IP and validated its mental health screening technology in veterans. The company raised $4.2 million to fund clinical development and expand its diagnostic portfolio.
Ada Torres
Ada Torres
24 Feb 2026
Radiopharm Theranostics has initiated dosing in its Phase 1/2a clinical trial of BetaBart, a novel radiotherapeutic developed with MD Anderson Cancer Center, targeting aggressive solid tumors.
Ada Torres
Ada Torres
24 Feb 2026
Telix Pharmaceuticals delivered a strong 56% revenue increase in 2025, driven by U.S. sales of Illuccix and the launch of Gozellix, while advancing its therapeutic pipeline and expanding global manufacturing capabilities. Despite a net loss, the company is investing heavily in R&D and sustainability initiatives aligned with climate-related disclosures.
Ada Torres
Ada Torres
20 Feb 2026
Cyclopharm has achieved a key milestone with Technegas approved for clinical use at the US National Institutes of Health, marking a strategic advance in its American expansion. Installation is imminent, leveraging a federal procurement framework that could broaden Technegas applications beyond pulmonary embolism.
Ada Torres
Ada Torres
18 Feb 2026
Telix Pharmaceuticals has lodged a European marketing authorization application for TLX101-Px, a novel PET imaging agent targeting glioma brain cancer, aiming to enhance diagnostic precision and patient access across major European markets.
Ada Torres
Ada Torres
18 Feb 2026
OncoSil Medical’s CEO Nigel Lange has agreed to a 10% salary reduction, opting instead to receive shares at a significant premium, reinforcing executive commitment to shareholder value and cost discipline.
Ada Torres
Ada Torres
12 Feb 2026
Racura Oncology has developed a pioneering blood test that promises to fast-track key data on its cardioprotective drug RC220, potentially shaving two years off the clinical trial timeline. This innovation also enhances patient safety and recruitment prospects in the ongoing RAC-010 CPACS trial.
Ada Torres
Ada Torres
11 Feb 2026
Algorae Pharmaceuticals has secured a key Licence & Supply Agreement with Cadila Pharmaceuticals to commercialise two generic cardiovascular and metabolic medicines in Australia and New Zealand, broadening its therapeutic reach beyond oncology.
Victor Sage
Victor Sage
9 Feb 2026
Immutep Limited has reached the halfway mark in enrolling patients for its global Phase III TACTI-004 trial, testing a novel immunotherapy combo in first-line non-small cell lung cancer. The trial remains on track for key milestones this year, signaling steady progress in a critical oncology space.
Ada Torres
Ada Torres
6 Feb 2026
OncoSil Medical Ltd has launched an $8 million equity raising to fund the commercial expansion and clinical development of its targeted radiotherapy device for pancreatic cancer, aiming to capitalise on growing European market adoption and upcoming trial catalysts.
Ada Torres
Ada Torres
3 Feb 2026
Invion Limited has secured a $2 million non-dilutive grant from the South Korean government to advance preclinical studies for oesophageal cancer, expanded its global Photosoft technology license, and raised $1.3 million via convertible notes to strengthen its financial position.
Ada Torres
Ada Torres
30 Jan 2026